Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

Published:2016 Issue:5 Volume:91 Page:251-260
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Calvo Emiliano,Braiteh Fadi,Von Hoff Daniel,McWilliams Robert,Becerra Carlos,Galsky Matthew D.,Jameson Gayle,Lin Ji,McKane Scott,Wickremsinhe Enaksha R.,Hynes Scott M.,Bence Lin Aimee,Hurt Karla,Richards Donald

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy;Cancers;2024-08-29

2. Rampant transcription replication conflict creates therapeutic vulnerability in extrachromosomal DNA containing cancers;2024-03-29

3. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer;Clinical Cancer Research;2022-11-15

4. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy;Biomedicine & Pharmacotherapy;2022-11

5. Targeting replication stress in cancer therapy;Nature Reviews Drug Discovery;2022-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP